<DOC>
	<DOCNO>NCT02012075</DOCNO>
	<brief_summary>The aim present study evaluate efficacy safety Extended-Release Carvedilol Sulfate versus Sustained-release Metoprolol Succinate Patients With Mild Moderate Chronic Heart Failure .</brief_summary>
	<brief_title>A Phase Ⅲ Study Extended-Release Carvedilol Sulfate Treatment Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<criteria>Males Females Aged 18 75 year New York Heart Association ( NYHA ) classification ⅡⅢ At screening , subject LVEF &lt; 0.45 Have receive optimal therapy Angiotensin convert enzyme inhibitor angiotensin receptor blocker 4 week enrollment Subjects symptom Stable heart failure need intravenous injection diuretic , cardiac inotropes vasodilator Willing provide write informed consent Current treatment Class I III antiarrhythmic , except amiodarone betablockers Current treatment calcium antagonists except longacting dihydropyridine agent Have history acute coronary syndrome , cerebral apoplexy transient ischemic attack 3 month Have history cardiovascular surgery vessel operation 3 month Have history sustain ventricular tachycardia ventricular fibrillation 3 month Have plan receive coronary revascularization heart transplantation Uncontrolled ventricular arrhythmia ( control antiarrhythmic therapy implantable defibrillator ) Subjects uncorrected primary obstructive severe regurgitative valvular disease，nondilated ( restrictive ) hypertrophic cardiomyopathy Sitting systolic blood pressure≤90mmHg ( base average 3 reading ) Current decompensated heart failure Second third degree heart block，or sick sinus syndrome，a pacemaker place Contraindication vasodilator Have history cardiac resynchronization therapy Have receive cardioverter defibrillator pacemaker 1 month Resting heart rate &lt; 50 beat per minute ( base average 3 reading ) Elevated liver enzyme ( alanine aminotransferase aspartate aminotransferase level great 3 time upper limit normal ) Serum creatinine level great 2 time upper limit normal Current clinical evidence obstructive pulmonary disease ( e.g. , asthma bronchitis ) require inhale oral bronchodilator steroid therapy History drug sensitivity allergic reaction alpha betablockers Contraindication intolerance betablockers Pregnant lactate woman woman plan become pregnant Has systemic disease , include cancer , reduce life expectancy ( &lt; 12 month ) Use investigational drug within 30 day enrollment Participation investigational device trial within 30 day enrollment Known drug alcohol abuse 1 year prior enrollment Has history psychological illness/condition interfere ability understand complete requirement study In opinion investigator subject know noncompliant prescribed medication regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>